Quantcast
Home > Quotes > CLRB

Cellectar Biosciences, Inc. Common Stock (CLRB) Quote & Summary Data

CLRB 
$1.9
*  
0.08
4.4%
Get CLRB Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading CLRB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
8.2
Today's High / Low
$ 1.90 / $ 1.82
Share Volume
35,213
50 Day Avg. Daily Volume
63,044
Previous Close
$ 1.82
52 Week High / Low
$ 14 / $ 1.22
Market Cap
9,039,793
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.26

Intraday Chart

Shares Traded

Share Volume:
35,213
50 Day Avg. Daily Volume:
63,044

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -345.44

Trading Range

The current last sale of $1.90 is 55.74% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.90 $ 14
 Low: $ 1.82 $ 1.22

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugateTM (PDCsTM) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDCTM platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations. Our lead PDC candidate, CLR 131, provides targeted delivery of the cytotoxic (cell-killing) radioisotope iodine 131. CLR 131 is in a Phase 1 clinical study for relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of other B-cell malignancies.  ... More ...  


Risk Grade

Where does CLRB fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.82
Open Date:
Feb. 15, 2019
Close Price:
$ 1.90
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info